Dimoveo is a pre-clinical stage medical device company that is developing a debridement device for cleaning and removing biofilm from the surgical cavity surrounding an implant. Dimoveo addresses the challenge of patients suffering from Post-TKA infection where current standard of care is ineffective. Dimoveo addresses the Global market, currently focusing on the US market with over 1.5M patients/year. Dimoveo is a portfolio company of MEDX Xelerator, backed by seed investment from Boston Scientific, MEDX Ventures and MEDX Xelerator. For more information, contact Dimoveo’s CEO, Yair Ramot: yair.r@dimoveomedical.com.